Results 81 to 90 of about 37,893 (278)

Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer

Molecular Therapy: Methods & Clinical Development, 2018
Newcastle disease virus (NDV) is a single-stranded, negative-sense RNA virus in the Paramyxoviridae family. Although primarily an avian pathogen, NDV is a potent oncolytic virus that has been shown to be safe and effective in a variety of preclinical ...
Lisa A. Santry, Thomas M. McAusland, Leonardo Susta, Geoffrey A. Wood, Pierre P. Major, Jim J. Petrik, Byram W. Bridle, Sarah K. Wootton   +7 more
doaj   +1 more source

Markedly enhanced intratumoral spread and antitumor effect of oncolytic adenovirus expressing decorin [PDF]

, 2008
With the aim of improving viral distribution and tumor penetration, we have engineered decorin expressing replication-incompetent (dl-LacZ-DCNG) and -competent (Ad-[DELTA]E1B-DCNG) adenoviruses.
A-Rum Yoon, Chae-Ok Yun, Daniela G. Seidler, Hoguen Kim, Il-Kyu Choi, Ji Young Yoo, Joo-Hang Kim, Young-Sook Lee   +7 more
core   +1 more source

Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity [PDF]

Frontiers in Oncology, 2014
Oncolytic viruses (OVs) selectively infect, replicate in, and kill tumor cells. For a long time, the therapeutic efficacy of OVs was thought to depend mainly on this mechanism of direct viral oncolysis. Nowadays, however, the post-oncolytic anti-tumor activity induced by the OV therapy is considered a key factor for an efficient therapeutic activity ...
Schirrmacher, Volker, Fournier, Philippe
openaire   +3 more sources

Viral hijacking of cellular metabolism. [PDF]

, 2019
This review discusses the current state of the viral metabolism field and gaps in knowledge that will be important for future studies to investigate.
Ch'ng, James, Christofk, Heather R, Thaker, Shivani K   +2 more
core  

Principles and Practice Guidelines of Microbiota Medicine: Statements From the CHINAGUT Conference

Microbiota Medicine Research, EarlyView.
The 2025 CHINAGUT Conference convened a panel of 48 clinicians from 39 hospitals in 5 countries to develop 15 key statements, aimed at providing clinicians, educators, and healthcare administrators with a comprehensive framework to advance education, clinical practice, research, and public popularization in microbiota medicine.
Faming Zhang, Zheshun Pi, Sunny Hei Wong, Vineet Ahuja, Serena Porcari, Dai Ishikawa, Hailong Cao, Linlin Chen, Ning Chen, Xiong Chen, Bota Cui, Xiao Ding, Xingxiang He, Jia Hu, Jiang Jin, Ji Li, Weiwei Liao, Jingmei Liu, Ling Liu, Yanyan Liu, Yaping Liu, Yu Liu, Chen Lu, Gaochen Lu, Muhan Lv, Xiangjun Meng, Yongzhan Nie, Qian Ren, Lixuan Sang, Xin Sun, Yang Sun, Hongliang Tian, Baohong Wang, Honggang Wang, Liangjing Wang, Xin Wang, Weihong Wang, Zheyu Wang, Yanling Wei, Quan Wen, Lihao Wu, Xia Wu, Lijing Xiong, Guoliang Ye, Bo Yi, You Yu, Yue Zeng, Huihong Zhai, Ting Zhang, Zulun Zhang, Li Zhou, Li Zhu, Kaichun Wu   +52 more
wiley   +1 more source

Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity

Molecular Therapy: Oncolytics, 2017
Oncolytic Semliki Forest virus (SFV) has been suggested as a potential candidate for the treatment of glioblastoma and neuroblastoma. However, the oncolytic capacity of SFV is restricted by the anti-viral type-I interferon (IFN) response. The aim of this
Tina Sarén, Mohanraj Ramachandran, Miika Martikainen, Di Yu   +3 more
doaj   +1 more source

Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication

Journal for ImmunoTherapy of Cancer, 2020
Background Oncolytic therapy uses live-replicating viruses to improve the immunological status of treated tumors. Critically, while these viruses are known to self-amplify in vivo, clinical oncolytic therapies still appear to display a strong dose ...
Eric Bartee, Erica B Flores, Bulent A Aksoy   +2 more
doaj   +1 more source

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. [PDF]

, 2007
We administered an adenoviral vector, Onyx-015, into the hepatic artery of patients with metastatic colorectal cancer involving the liver. Thirty-five patients enrolled in this multi-institutional phase I/II trial received up to eight arterial infusions ...
Au, T, Kirn, D, Korn, WM, Reid, TR, Sze, D, Thorne, S   +5 more
core  

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

Oncolytic virus immunotherapy: future prospects for oncology [PDF]

Journal for ImmunoTherapy of Cancer, 2018
Immunotherapy is at the forefront of modern oncologic care. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. One emerging class in both primary and salvage therapy is oncolytic viruses.
Raja, Junaid, Ludwig, Johannes M., Gettinger, Scott N., Schalper, Kurt A., Kim, Hyun S.   +4 more
openaire   +4 more sources